Research To Practice | Oncology Videos

Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics: Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond gastroesophageal cancer (0:00) Dual HER2 inhibition in the treatment of HER2-amplified colorectal cancer (CRC) (4:56) Efficacy and tolerability of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic CRC (8:52) Activity and safety of the novel bispecific antibody zanidatamab for previously treated HER2-amplified biliary tract cancer (BTC) (14:11) Key findings with tucatinib/trastuzumab for previously treated HER2-positive BTC (21:56) Antitumor activity observed with T-DXd in patients with BTC with HER2 mutations in the Phase II DESTINY-PanTumor02 trial (23:39) CME information and select publications

Featuring an interview with Dr Kanwal Raghav, including the following topics: Activity and tolerability of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing colorectal cancer (CRC) (0:00) Case: A woman in her mid 50s with multiregimen-refractory metastatic CRC receives T-DXd on a clinical trial (11:19) Case: A woman in her early 60s with advanced intrahepatic cholangiocarcinoma receives zanidatamab on a clinical trial (18:11) Molecular pathways and mechanisms of HER2 in cancer; clinical implications and future directions for gastrointestinal cancers (20:33) Evolving paradigm surrounding HER2 and other oncogene-addicted targets (29:32) CME information and select publications

Featuring perspectives from Dr Bita Fakhri, including the following topics: Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00) 6-year follow-up from the Phase III CLL14 trial of first-line venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for chronic lymphocytic leukemia (CLL) (7:36) Updates from ASH 2023 from the Phase III FLAIR study of minimal residual disease (MRD)-guided ibrutinib in combination with venetoclax for previously untreated CLL (13:28) 57-month follow-up from the Phase III GLOW trial of fixed-duration ibrutinib/venetoclax for previously untreated CLL (22:28) Current clinical role of MRD testing for CLL (28:11) Key findings from 5-year follow-up of the Phase II CAPTIVATE study for patents with CLL/small lymphocytic leukemia (SLL) with relapse after first-line fixed-duration ibrutinib/venetoclax (36:43) 6-year update from the Phase III ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for treatment-naïve CLL (41:57) Updates from ASH 2023 for the management of relapsed/refractory CLL (54:30) Recent updates for the management of double-refractory CLL (58:05) Novel therapies under investigation for patients with CLL/SLL (1:10:57) Key findings guiding the clinical management of Richter's transformation (1:13:44) Case: A man in his early 80s with IGHV-unmutated del(17p) CLL experiences disease progression 3 years after completing second-line venetoclax-based therapy (1:22:17) CME information and select publications

Featuring perspectives from Prof Thierry André and Dr Arvind Dasari, including the following topics: Introduction: Year in Review on the Ground (0:00) Treatment of HER2-Positive Colorectal Cancer (CRC) (7:50) Immune Checkpoint Inhibitors for Microsatellite Instability-High CRC (24:12) Other Key Issues (45:30) Questions and Cases from the Community (52:30) CME information and select publications

Featuring perspectives from Dr Shilpa Gupta and Prof Thomas Powles, including the following topics: Introduction: The Cancer-Immunity Cycle (0:00) Nonmetastatic Urothelial Bladder Cancer — Dr Gupta (7:30) Metastatic Urothelial Bladder Cancer — Prof Powles (33:06) CME information and select publications

Featuring perspectives from Dr Manish Patel, including the following topics: Insights into a comprehensive clinical research practice (0:00) Transformation of the conduct and design of clinical trials (3:41) Disparities and conundrums in clinical trial recruitment (10:11) Rationale of clinical trial dosing and regulatory initiatives (15:37) Innovation and advancements in oncology research and clinical development (18:47) Practical considerations into patient care during a clinical trial (20:52) Encouraging physicians to participate in oncology research (24:29) Pharmacology of B7-H3 and role in tumor pathogenesis (31:56) Current and future clinical development of ifinatamab deruxtecan (I-DXd) (34:11) Available clinical data with vobramitamab duocarmazine across numerous solid tumors (1:02:44) Early clinical data with HS-20093 for advanced solid tumors (1:06:36) CME information and select publications

Featuring perspectives from Dr Robin (Katie) Kelley and Dr Mark Yarchoan, including the following topics: Introduction: Interdisciplinary Management of Hepatocellular Carcinoma (HCC) in the Community (General Medical Oncology) Setting — Radiology, Hepatology, Pathology Support (0:00) Potential Role of Anti-PD-1/PD-L1 Antibodies in the Care of Patients with Early- and Intermediate-Stage HCC — Dr Yarchoan (8:09) HCC Rounds (22:07) Tolerability and Other Practical Considerations with the Use of Immune Checkpoint Inhibitors for Advanced HCC and Biliary Tract Cancers (BTCs) — Dr Kelley (39:25) Faculty Survey (49:19) BTC Rounds (52:19) CME information and select publications

Featuring perspectives from Dr Melissa Johnson, including the following topics: Role of biomarker testing in optimal selection of first-line therapy for patients with non-small cell lung cancer (NSCLC) (0:00) Efficacy and safety with datopotamab deruxtecan for previously treated NSCLC (15:45) Antitumor activity with and current status of CEACAM5-targeted therapy for relapsed NSCLC (30:24) Evolution of drug development and clinical research (37:56) Key findings with sacituzumab govitecan for NSCLC (41:59) Telisotuzumab vedotin for patients with NSCLC and MET expression (48:44) Recent findings with tumor treating fields for metastatic NSCLC after disease progression on platinum-based therapy (50:49) Other novel antibody-drug conjugates under investigation for NSCLC (55:26) Case: A woman in her mid 50s with recurrent extensive-stage small cell lung cancer who developed pneumonitis on ifinatamab deruxtecan (59:05) Case: A woman in her early 60s with complete response to dose-reduced patritumab deruxtecan (1:00:15) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 2: Triple-Negative Breast Cancer — Priyanka Sharma, MD CME information and select publications

Featuring perspectives from Dr Ian E Krop and Dr Priyanka Sharma, including the following topics: Introduction: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024 (0:00) HER2-Positive Breast Cancer — Dr Krop (12:30) Triple-Negative Breast Cancer — Dr Sharma (36:34) CME information and select publications